{"id":"regdanvimab","rwe":[],"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"J06BD06","category":"atc"},{"label":"Active","category":"status"},{"label":"COVID-19","category":"indication"},{"label":"Celltrion Healthcare Hungary Kft.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Celltrion Healthcare Hungary Kft.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=REGDANVIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:19:28.224353+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:19:35.134914+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:19:28.250802+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REGDANVIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:19:35.941837+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Spike glycoprotein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:19:36.519226+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650462/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:19:36.408481+00:00"}},"allNames":"regkirona","offLabel":[],"synonyms":["regdanvimab","regkirona","CT-P59"],"timeline":[{"date":"2021-11-12","type":"positive","source":"DrugCentral","milestone":"EMA approval (Celltrion Healthcare Hungary Kft.)"}],"approvals":[{"date":"2021-11-12","orphan":false,"company":"CELLTRION HEALTHCARE HUNGARY KFT.","regulator":"EMA"}],"brandName":"Regkirona","ecosystem":[{"indication":"COVID-19","otherDrugs":[{"name":"bamlanivimab","slug":"bamlanivimab","company":"Eli Lilly and Company"},{"name":"casirivimab","slug":"casirivimab","company":"Regeneron Pharmaceuticals, Inc."},{"name":"etesevimab","slug":"etesevimab","company":"Eli Lilly and Company"},{"name":"imdevimab","slug":"imdevimab","company":"Regeneron Pharmaceuticals, Inc."}],"globalPrevalence":null}],"mechanism":{"modality":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"Regkirona is a monoclonal antibody that binds to the SARS-CoV-2 spike protein, preventing the virus from binding to and entering host cells through the angiotensin-converting enzyme 2 (ACE2) receptor."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5501","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=REGDANVIMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REGDANVIMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:31:08.530174","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:19:38.563921+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"palivizumab","drugSlug":"palivizumab","fdaApproval":"1998-06-19","relationship":"same-class"},{"drugName":"ansuvimab","drugSlug":"ansuvimab","fdaApproval":"2020-12-21","relationship":"same-class"},{"drugName":"casirivimab","drugSlug":"casirivimab","fdaApproval":"2020-11-21","relationship":"same-class"},{"drugName":"imdevimab","drugSlug":"imdevimab","fdaApproval":"2020-11-21","relationship":"same-class"},{"drugName":"nirsevimab","drugSlug":"nirsevimab","fdaApproval":"2023-07-17","relationship":"same-class"}],"genericName":"regdanvimab","indications":{"approved":[{"name":"COVID-19","source":"DrugCentral","snomedId":840539006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"palivizumab","brandName":"palivizumab","genericName":"palivizumab","approvalYear":"1998","relationship":"same-class"},{"drugId":"ansuvimab","brandName":"ansuvimab","genericName":"ansuvimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"casirivimab","brandName":"casirivimab","genericName":"casirivimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"imdevimab","brandName":"imdevimab","genericName":"imdevimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"nirsevimab","brandName":"nirsevimab","genericName":"nirsevimab","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05982704","phase":"PHASE4","title":"Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19","status":"UNKNOWN","sponsor":"City Clinical Hospital No.52 of Moscow Healthcare Department","startDate":"2022-08-18","conditions":["Coronavirus Infections"],"enrollment":82,"completionDate":"2023-11-01"},{"nctId":"NCT04602000","phase":"PHASE2,PHASE3","title":"A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-10-05","conditions":["SARS-CoV-2 Infection"],"enrollment":1642,"completionDate":"2021-10-20"},{"nctId":"NCT05439044","phase":"","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-01","conditions":["Immunocompromised Patients"],"enrollment":4000,"completionDate":"2022-12-31"},{"nctId":"NCT04593641","phase":"PHASE1","title":"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-09-04","conditions":["SARS-CoV-2 Infection"],"enrollment":18,"completionDate":"2021-04-05"},{"nctId":"NCT04525079","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-07-18","conditions":["SARS-CoV-2 Infection"],"enrollment":32,"completionDate":"2020-11-05"}],"_emaApprovals":[{"date":"2021-11-12","status":"Authorised","company":"CELLTRION HEALTHCARE HUNGARY KFT."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018944","UNII":"I0BGE6P6I6","INN_ID":"11883","UMLSCUI":"C5432268","chemblId":"CHEMBL4650462","ChEMBL_ID":"CHEMBL4650462","KEGG_DRUG":"D12241","DRUGBANK_ID":"DB16405","IUPHAR_LIGAND_ID":"11332","MESH_SUPPLEMENTAL_RECORD_UI":"C000716788"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Celltrion Healthcare Hungary Kft.","relationship":"Original Developer"}],"publicationCount":58,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J06BD06","allCodes":["J06BD06"]},"biosimilarFilings":[],"originalDeveloper":"Celltrion Healthcare Hungary Kft.","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Celltrion Healthcare Hungary Kft.","companyId":"celltrion","modality":"Monoclonal antibody","firstApprovalDate":"2021","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:19:38.563921+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}